Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01761019
Recruitment Status : Completed
First Posted : January 4, 2013
Results First Posted : September 21, 2016
Last Update Posted : September 21, 2016
LEO Pharma
Information provided by (Responsible Party):
Laura Ferris, University of Pittsburgh

Brief Summary:
Oral therapies for psoriasis, including methotrexate and acitretin, are often less effective when used as monotherapy (without other oral medicines or creams) than are newer biologic injected drugs. However, these oral medications are also less expensive than biologic agents and may be safer for use in some patients. The purpose of this study is to determine if adding a topical psoriasis medicine, calcipotriene/betamethasone topical suspension (Taclonex topical suspension), will improve the severity of psoriasis in patients already on methotrexate or acitretin and to determine if adding this topical suspension will reduce the desire of such patients to switch to a biologic agent to treat their psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Taclonex Topical Suspension Phase 4

Detailed Description:

Many patients with mild psoriasis are able to control disease symptoms with topical medications alone. There are a variety of topical options available, including corticosteroids, synthetic vitamin D3, vitamin A, coal tar, salicylic acid and a number of other products of varying efficacy. The combination topical suspension of calcipotriene 0.005% and betamethasone dipropionate 0.064% is a first-line treatment for moderate to severe psoriasis vulgaris and is FDA approved for use on the skin and scalp in adults 18 years and older. This treatment combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. It is well tolerated and has a low rate of adverse events according to pooled safety data from 2700 patients who have used a calcipotriene/betamethasone combination in clinical trials. Calcipotriene/betamethasone topical suspension has also been shown to have a positive impact on patient quality of life, as seen in clinical trials utilizing patient reported outcomes such as the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index.

Calcipotriene/betamethasone topical suspension is a therapy commonly used to treat patients with mild to moderate psoriasis. Currently, there have been no formal trials studying the efficacy of calcipotriene/betamethasone topical suspension used in conjunction with methotrexate or acitretin. In order to better understand the effectiveness of this treatment combination, we conducted a preliminary, open label, single arm prospective study to determine the benefit of adding betamethasone-calcipotriene topical suspension to ongoing systemic psoriasis therapy in subjects who do not have complete clearance of psoriasis on a single systemic agent alone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Study Start Date : January 2013
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Daivobet

Arm Intervention/treatment
Taclonex topical suspension
Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
Drug: Taclonex Topical Suspension
topical medication for psoriasis

Primary Outcome Measures :
  1. Investigator Global Assessment [ Time Frame: 12 weeks ]
    This is score from 0-5 that measures, in the opinion of the study doctor, the severity of psoriasis on a subject, with 5 being most severe and 0 least severe. The change in this score between baseline and week 12 will be measured.

Secondary Outcome Measures :
  1. Body Surface Area [ Time Frame: 12 weeks ]
    This is a measure of the percentage of the body involved with psoriasis. We will measure the change in percentage of body area involved with psoriasis from baseline to week 12.

  2. Safety [ Time Frame: 12 weeks ]
    Throughout this study, adverse events and serious adverse events will be collected

  3. Patient Satisfaction [ Time Frame: 12 weeks ]
    • Subject satisfaction: We also ask subjects for their level of satisfaction with their current treatment at week 12. They will be given the following options: "very satisfied", "satisfied", "somewhat disappointed" or "very disappointed". For measurement "very satisfied"=4, "satisfied"=3, "somewhat disappointed"=2 and "very disappointed"=1. We will determine the mean satisfaction of all patients at week 12.

  4. Desire to Change to Another Systemic Therapy [ Time Frame: 12 weeks ]
    We will measure the difference in percent of subjects who wish to change to another systemic therapy at baseline vs at week 12.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects age 18 years and older with stable plaque psoriasis of duration of at least 6 months.
  • Subject must be currently using a stable dose, with stable disease severity, of a single non-biologic systemic psoriasis medication (methotrexate or acitretin) for at least 2 months.
  • Subject must be planning to continue current systemic agent, and standard of care monitoring for that medication
  • All labs required for methotrexate or acitretin will be done according to standard of care.
  • If a woman, before entry she must be: Postmenopausal, or practicing a highly effective method of birth control
  • Women of childbearing potential must have a negative urine pregnancy test prior to randomization
  • Subject must be able and willing to provide written informed consent to participate.

Exclusion Criteria:

  • Non-plaque psoriasis (pustular, erythrodermic, or guttate).
  • Use of excluded therapies: phototherapy use currently or in the 4 weeks prior to baseline, use of more than 1 systemic therapy in the 2 months prior to baseline, use of topical steroid, tar preparation, or vitamin D analog in the 4 weeks prior to baseline.
  • Subjects who are currently taking or have taken in the past 60 days, for any reason, any medication that, in the opinion of the investigator, suppressed the immune response. This may include but is not limited to systemic steroids, azathioprine, cyclosporine, FK506, mycophenolate mofetil, mycophenolic acid, etanercept, adalimumab, infliximab, ustekinumab, cimzia, or any other biologic agent targeted to any cell or cytokine in the immune system.
  • Subjects with any use at any time in the past of Taclonex topical suspension or Taclonex ointment
  • Subjects who are pregnant, nursing, or plan on becoming pregnant during the course of the study.
  • Presence of any unstable medical or psychiatric condition that, in the opinion of the investigator, could impair subject compliance.
  • Subject has any active infection within 30 days prior to baseline.
  • Known or suspected disorders of calcium metabolism
  • Known or suspected severe kidney or liver disease.
  • Known or suspected hypersensitivity to component(s) of the investigational products.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01761019

Layout table for location information
United States, Pennsylvania
UPMC Department of Dermatology, Falk Clinic
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
LEO Pharma
Layout table for investigator information
Principal Investigator: Laura Ferris, MD, PhD University of Pittsburgh
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Laura Ferris, MD, PhD, University of Pittsburgh Identifier: NCT01761019    
Other Study ID Numbers: PRO12100308
First Posted: January 4, 2013    Key Record Dates
Results First Posted: September 21, 2016
Last Update Posted: September 21, 2016
Last Verified: August 2016
Keywords provided by Laura Ferris, University of Pittsburgh:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases